Journal
LEUKEMIA & LYMPHOMA
Volume 51, Issue 6, Pages 1020-1027Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/10428191003746331
Keywords
Cell-free DNA; circulating DNA; Epstein-Barr virus; quantitative PCR; viral load; B-non-Hodgkin lymphoma
Categories
Funding
- Swiss Bridge Foundation, Switzerland
- Conselho Nacional de Desenvolvimento Cientifico e Technologico (CNPq) [400801/2005-1]
- FAPERJ-APQ1-Processo [E-26/171.479/2006]
Ask authors/readers for more resources
Tumor-derived DNA is elevated in the plasma of patients with cancer. The analysis of circulating DNA may be useful for diagnosis, prognosis evaluation, and early detection of disease recurrence. In order to investigate cf-DNA as a marker during treatment, we serially quantified total cell-free (cf) and EBV plasma DNA in 30 cases of pediatric B-non-Hodgkin lymphoma by real-time PCR. The cf-DNA levels were significantly increased in patient samples at diagnosis as compared with the healthy controls (p < 0.001). At the end of treatment, a significant decrease in plasma DNA concentration was observed as compared with values observed at diagnosis (median: 94.0 copies/mL, p = 0.001). EBV was detected by ISH in 7/30 patients. Plasma EBV DNA levels were obtained from seven EBV-positive patients (median: 1278 copies/mL), while EBV DNA was not detected in 23 EBV-negative patients and 10 healthy controls. The association between the two methods of detection was statistically significant, with 100% correlation (Kappa coefficient, p = 1). In addition, the decrease of EBV viral load was associated with therapy response. Quantification of plasma EBV DNA may become a valuable source for disease detection of pediatric EBV-associated lymphomas and for monitoring treatment response.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available